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Acute ischemic stroke treatment,
part 1: patient selection
“The 50% barrier and the capillary
index score”
Firas Al-Ali 1*, John J. Elias 2, Danielle E. Filipkowski 2 and James E. Faber 3
1 Summit Neurovascular Specialists, Akron, OH, USA, 2 Department of Research, Akron General Medical Center, Akron, OH,
USA, 3 Department of Cell Biology and Physiology, University of North Carolina School of Medicine, Chapel Hill, NC, USA
The current strategy for intra-arterial treatment (IAT) of acute ischemic stroke focuses
on minimizing time from ictus to revascularization and maximizing revascularization.
Employing this strategy has yet to lead to improved rates of successful outcomes.
However, the collateral blood supply likely plays a significant role in maintaining viable
brain tissue during ischemia. Based on our prior work, we believe that only approximately
50% of patients are genetically predisposed to have sufficient collaterals for a good
outcome following treatment, a concept we call the 50% barrier. The Capillary Index Score
(CIS) has been developed as a tool to identify patients with a sufficient collateral blood
supply to maintain tissue viability prior to treatment. Patients with a favorable CIS (fCIS)
may be able to achieve a good outcome with IAT beyond an arbitrary time window. The
CIS is incorporated into a proposed patient treatment algorithm. For patients suffering
from a large stroke without aphasia, a non-enhanced head CT should be followed by CT
angiography (CTA). For patients without signs of strokemimics or visible signs of structural
changes due to large irreversible ischemia, CTA can help confirm the vascular occlusion
and location. The CIS can be obtained from a diagnostic cerebral angiogram, with IAT
offered to patients categorized as fCIS.
Keywords: acute ischemic stroke, patient selection, the 50% barrier, intra-arterial treatment, capillary index score,
revascularization, stroke outcome
Introduction
The current strategy for acute ischemic stroke (AIS) treatment is based on two pillars: time
from ictus to revascularization (TIR) and revascularization success as measured by the modified
thrombolysis in cerebral ischemia scale (mTICI). The assumption is that clinical outcome following
AIS is dependent on the interaction of these two factors. The shorter the TIR and the higher the
mTICI, the better the outcome. It follows that the strategy behind current intra-arterial treatment
for acute ischemic stroke (IAT-AIS) is the faster and more complete the revascularization, the better
the clinical outcome. However, despite the recent impressive improvement in revascularization rates
and decrease in time to revascularization, until recently the clinical improvement rate remained
unchanged at approximately 40–45% (Table 1) with a ratio of good clinical outcome (GCO) in
treatment vs. control arms of approximately 1.7 (1–11). Recent trials have published GCOs above
50% in the treatment arm, but with the same ratio of GCOs between the treated and untreated arms
around 1.7 (12, 13). How we can explain this consistency? A fresh look at our strategy and selection
criteria is obviously warranted.
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TABLE 1 | Clinical outcomes across IAT-AIS trials.
Trial % mRS 0–2 (3months) Time to IAT (h) % TIMI 2, 3
PROACT II 42.3a 4.5b 58
IMS I 43 3.050.8b 56
IMS II 46 n/a 64
IMS III 40.8 3.5b 81d
SYNTHESIS 41.9 3.45c n/a
SWIFT 37 4.9b 83
TREVO 2 39.9 4.7c 90
MR CLEAN 32.6 4.3c 58.7d
EXTEND-IA 71 3.5c 86d
ESCAPE 53 3.1c 72.4d
aBarthel Index 9 and 10.
bMean.
cMedian.
dTICI 2, 3 for M1 occlusion.
Physiological Background and the 50%
Barrier
Normal cerebral blood flow (CBF) is 50–55ml/100 g/min (14,
15). AIS induces a rapid and sustained reduction in CBF. Clin-
ical signs of ischemia generally become apparent when CBF
drops below 23ml/100 g/min (16). If residual CBF (rCBF) further
decreases to 15–16ml/100 g/min, the cortical-evoked potential
ceases within seconds (16). The rate of depression of the evoked
potential (EP) amplitude (expressed in units of percent of con-
trol/min) is highly correlated with the residual flow, following
a linear relationship with the regression line intercepting the
flow axis at 15.2ml/100 g/min (17). The data strongly suggest a
threshold-like relationship also exists between the amplitude of
the EP and local blood flow. If flow is greater than approximately
16ml/100 g/min the EP is not affected, but at flows less than
approximately 12ml/100 g/min the EP is abolished (17). Neither
the clinical signs of ischemia nor cessation of the EP is syn-
onymous with cell death, but cessation of the EP is one of the
final stages before irreversible injury (infarction). Its physiological
purpose is to conserve energy by decreasing cell metabolism
to the minimal level possible; however, cell death ensues there-
after.
Similarly, the relationship between time to irreversible dam-
age and rCBF is well-documented (18). In one study, rCBF in
monkeys wasmeasured in the ischemic area with time after occlu-
sion until irreversible tissue damage occurred (16). An infarction
threshold was observed relating the rCBF to time between the
initial drop in CBF to irreversible ischemia (Figure 1). This work
confirmed prior studies using the neuronal EP and showed that
when rCBF reached a low level of around 10ml/100 g/min, the
available time to salvage the brain tissue was extremely short
(<1 h) (16).
The depth of ischemia, i.e., the level of rCBF, will vary from
patient to patient depending on the available retrograde pial collat-
erals to the ischemic area. The major determinants of the amount
of collateral perfusion are the number and diameter of these pial
collaterals, plus perfusion pressure and resistance above and below
the collateral network. Greater collateral numbers and diameters
sustain a higher rCBF, thus more salvageable brain and a smaller
final infarct volume.
FIGURE 1 | Depth of ischemia and time to irreversible cerebral
damage: time to irreversible cerebral damage depends on the depth
of ischemia, which depends on the pial collateral supply to the
ischemic territory. Since different patients have different collaterals, the
depth of ischemia will vary among patients, as will the time available for
therapy to salvage the tissue (16).
Following AIS, rCBF stays virtually unchanged if spontaneous
recanalization of the occluded blood vessels does not occur (16,
18, 19).While the clinical symptoms of ischemia will often resolve
if CBF is restored promptly, prolonged low levels of rCBF leads
to irreversible brain tissue damage. Since the time of ischemia
that the brain tissue can tolerate before irreversible damage ensues
depends on the rCBF value, which is patient-specific and highly
dependent on the collaterals, it follows that every patient has his or
her own time (Figure 1) (16, 18, 19). Hence, if we correctly select
patients that are optimal candidates (patients with ischemic but
viable tissue) and are able to achieve safe, full, and timely revascu-
larization (prior to irreversible ischemic damage occurring), the
clinical symptoms of a stroke should improve significantly and
rather quickly.
Given this information, the most logical explanation for the
remarkably consistent results of the different IAT-AIS trials, with
<50%GCOs (modified Rankin Score, or mRS,2), is that around
half of treated patients have poor pial collaterals, thus causing
them to have a relatively low rCBF such that they enter into
irreversible ischemia before therapy can be administered, even
when timely (within 6 h) revascularization is achieved. This obser-
vation implies a potential ceiling effect for IAT-AIS; we call this
phenomenon the 50% barrier (Figure 2).
The Genetic Factor?
Why is there such variability in collateral-dependent flow in
patients with AIS, as exemplified by the above and many other
studies? (21) Could the number and diameter (i.e., extent) of
cerebral collaterals vary among individuals? While we do not
have answers for humans yet, recent studies in mice suggest the
answermay be yes and that genetic backgroundmay be important.
In mice, pial collaterals form late in gestation, after the cerebral
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FIGURE 2 | Logarithmic time curve: the infarction threshold distinguishing between reversible and irreversible ischemia as a function of rCBF and
time from ictus. Time window here is an approximation. The vertical lines are an approximation and have not yet been validated (20).
artery trees are well-established (22, 23). Likewise in humans,
the middle cerebral artery (MCA) tree is already well-established
by 9weeks gestation, with pial collaterals beginning to appear
by 14weeks (24, 25). Collateral formation occurs by a unique
process, termed collaterogenesis, that differs significantly from
development of the general arterial–venous circulation;moreover,
this process determines the collateral extent present in the adult
(22, 23). Interestingly, naturally occurring differences in genetic
background, which have no discernible effect on formation of the
general circulation or its extent and function in the adult, have
profound effects on collaterogenesis (23, 26). Thus, the extent
of the pial collaterals in the neocortex varies by 56-fold among
21 mouse strains with different genetic backgrounds, resulting
in a 30-fold variation in infarct volume after MCA occlusion
(27–29). A single polymorphic locus on chromosome 7, denoted,
“Determinant of collateral extent-1 (Dce1),” has been identified
as causal for more than 80% of this variation, as exemplified in
the two index strains (30). In that study, congenic methods were
used to replace the at-risk allele of Dce1 in the strain with poor
collaterals with the allele from the strainwith abundant collaterals.
This restored the poor collateral phenotype to nearly that in the
good strain, i.e., 83% correction of low collateral extent, and – after
MCA occlusion – a 4.5-fold increase in blood flow in the territory
at risk and 85% reduction of final infarct volume. Thus, ischemia
and infarct volume were strongly reduced by exchanging a single
genetic locus (30). These findings demonstrate that theDce1 locus
harbors a critical link in the pathway that controls collaterogene-
sis. Although the causative genetic element(s) at Dce1 is not yet
known, several candidate genes have been identified (30). Since
the pathways that control vascular development in the embryo are
highly conserved among vertebrates, the same or a closely related
gene(s) is likely to contribute to the wide variation in collateral
status in humans. A prospective multi-center study, “Genetic
Determinants of Collateral Status in Stroke (GENEDCSS) has
been initiated to test this hypothesis (31). This study will deter-
mine if variation in collateral score, stroke severity, functional
recovery, and other outcomes are linked to a polymorphism(s) at
human Dce1 and/or at several related candidate genes in patients
with acute MCA stroke.
One’s genetic backgroundmay not be the only factor that causes
variation in collateral extent. Environmental factors also cause
collateral insufficiency, at least in mice, although the magnitude
of their impact has thus far not approached that of genetic back-
ground. Thus, aging (32), other cardiovascular risk factors such
as hypertension, metabolic syndrome, and diabetes (33), as well
as endothelial dysfunction per se (34), cause loss of pial collat-
erals and reduced diameter of those that are still present (collat-
eral rarefaction). This rarefaction is accompanied by substantial
increases in infarct volume after MCA occlusion. These findings
have recently found support in patients with AIS(21).
It is also important to note that variation in the extent of
the anterior communicating artery (ACom) and posterior com-
municating artery (PCom) collaterals is well-known to exist in
humans, including those with acute stroke. The contributions of
genetic, environmental, and stochastic factors to this variation
are unknown, although they are currently under investigation in
mice (JE Faber, personal communication). Moreover, the extent
to which such variation combines with variation in pial collaterals
to impact rCBF remains to be determined.
How might identification of a “collateral gene” like Dce1 in
mice benefit patients with acute stroke? A biomarker for collateral
extent would provide a rapid point-of-care test to aid imaging
methods, used during stroke triage to measure collateral status
(e.g., conventional angiography and CT/MR perfusion), to help
tailor the time-window for treatment with intravenous and/or
endovascular recanalization therapies. A genetic marker of col-
lateral abundance would also help stratify patients to reduce the
presumed large contribution of collateral differences to the vari-
ability seen in past trials, and help more accurately assess the
merit of the treatment used (e.g., intra-venous vs. intra-arterial vs.
embolectomy). Identifying a risk allele for collateral insufficiency
in humans would also be prognostic, adding to our understanding
of why some patients doworse than others. Eventual identification
of the causal gene(s) at Dce1may also provide therapeutic targets
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FIGURE 3 | Calculating the capillary index score (CIS). A frontal view of
normal diagnostic cerebral angiogram. The territory of the middle cerebral
artery (MCA) is being used as an example of an ischemic territory. The
ischemic territory is divided into three equal sections; each section is given a 1
if it exhibits capillary blush, or a 0 if no capillary blush is present. The CIS is the
sum of these three numbers. CIS can range from a score of 0 to 3 (20, 61).
aimed at the collateral circulation for future development. Healthy
individuals carrying the risk polymorphism could be encouraged
to adopt lifestyles and treatments to avoid acquiring risk factors for
cardiovascular disease and stroke that have been found in animal
studies (22, 30, 31) [with support coming in human studies (4)]
to cause progressive loss of collaterals and increased severity of
stroke.
Patient Selection
Current Imaging Selection Tests: Non-Invasive
Neuroimaging
Diffusion MRI
Diffusion MRI is the best available method for the early detection
of infarct core (35–38). Acute infarction produces a high contrast
abnormality on diffusion-weighted images (DWI), the volume of
FIGURE 4 | CIS=0. In this patient with proximal left middle cerebral artery
occlusion, we can calculate the CIS from this injection only since the only
other potential collateral to the MCA territory is from the left posterior cerebral
artery (PCA), which is filled in the injection through the posterior
communicating artery (Pcom, arrow). If we divide the ischemic territory (Lt
MCA territory) into three sections, none of these sections exhibit a capillary
blush, late in the venous phase; therefore, the CIS= 0.
which is relatively simple to quantify (39). The high contrast-to-
noise (CNR) ratio of DWI makes it accurate. DWI abnormalities
sometimes reverse (40), but this is rare (41) and when it occurs it
usually involves only a small part of the lesion (42). Additionally,
a DWI reversal is often a pseudo-reversal in that such tissue
proceeds to infarction despite apparent temporary normalization
of the DWI signal abnormality (42).
Studies have shown that aDWI abnormality volumeof >70ml is
highly specific for a poor outcome (43, 44), and that this threshold
volume is useful in selecting patients for endovascular interven-
tion (45, 46). This threshold was successfully employed in the
Diffusion and Perfusion Imaging Evaluation for Understanding
Stroke Evolution Study II (DEFUSE II) trial (42). The use of early
infarct “core” identification for triage decisions is supported by the
observations that the final infarct volume is the single best predic-
tor of good outcome at 90 days (39, 40). As has been shown (47),
good outcomes are observed in nearly half such patients when the
final infarct volume is 60ml or less. The rate of good outcomes
rapidly declines with infarcts that are larger. The use of a 70ml
DWI volume threshold (48) to successfully guide endovascular
treatment was recently independently verified in a study at the
Cleveland Clinic (49).
CT
CT is a front-line imaging modality for acute stroke because it
is reliable for detecting hemorrhage. Moreover, CT angiography
(CTA) may be subsequently acquired. However, non-contrast CT
is unreliable for detecting the early infarct core (50, 51). It is highly
specific for infarction when a hypodensity is clearly visible, but
such changes typically occur late.
CT Perfusion
Much research has been devoted to developing CTP techniques
for identification and quantification of the early infarct core.
However, it is not sufficiently reliable for this purpose. This is
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FIGURE 5 | CIS= 1. (A) Occlusion of intracranial right ICA. (B) Injection of
the left ICA demonstrates absence of the Acom; hence, no cross filling to the
right hemisphere from this injection (ischemic territory= right middle and right
anterior carotid arteries). (C) Injection of the right vertebral artery
demonstrates partial opacification of the temporal and parietal lobes through
the right PCA via pial collaterals. (D) Delayed combined venous phase of the
left internal carotid and right vertebral showing only one-third of the ischemic
territory (right middle cerebral and interior cerebral arteries) territory
demonstrates capillary blush. CIS= 1.
because it is amethod that has inherently low signal-to-noise ratio
(SNR) and CNR, producing “noisy” images with high measure-
ment error (46, 52). Proponents of CTP may have been misled by
correlation and regression studies of CTP-derived parameters in
comparison to DWI or another gold standard. These studies typi-
cally show statistically significant correlations. Some investigators
extrapolate a high correlation in a population of measurements
to high accuracy of the measurement in an individual. This is
not valid (53). A recent evidence-based analysis of diffusion and
perfusion imaging in stroke by the Therapeutics and Technology
Assessment Subcommittee of the American Academy of Neurol-
ogy found that diffusion MR was a Level A/Class I method, but
found insufficient evidence to even classify perfusion imaging
(37). Furthermore, CTP typically only encompasses a limited
number of slices and often fails to capture even half the tissue
volume at risk for infarction that one is interested in determining
infarction volume in.
There is no consensus on how to best apply CTP. A variety of
acquisition parameters have been used, as well as many different
data processing methods. Additionally, different parameters (e.g.,
cerebral blood volume, CBV, or CBF thresholds) have been pro-
posed for defining infarcted tissue (54). It is thought that standard-
ization and validation will make CTP viable (53). However, CTP is
unlikely to become a reliable method (46, 52). Theory informs us
that CBVmay be elevated or depressed in core tissue and thus it is
not useful. This has been empirically confirmed (55). CBF is more
capable of estimating the infarct core. The reasoning is that below
a certain CBF threshold, brain tissue is very likely to be viable only
for a short period of time. However, there are major problems that
are related to the underlying imaging physics: the CNR of infarct
cores on CTP-derived CBF images are very low (52). At its current
state, the errors in CTP-derived estimates of CBF are too high to
be used to reliably guide treatment in an individual patient with a
severe anterior circulation stroke.
The Limitations of Non-Invasive Testing
Despite its promise, the merit of any non-invasive imaging test
in patient selection for AIS treatment has yet to be proven in a
multicenter, prospective, randomized clinical trial. Furthermore,
the issue of what is considered acceptable sensitivity, specificity,
and positive predictive value of these screening tests has not yet
been addressed.
In a recent paper, Alberta Stroke Program Early CT (ASPECT)
score was not found to help in patient selection in AIS to predict
outcome (56). Even MRI diffusion and perfusion imaging did
not demonstrate a strong enough positive predictive value where
only approximately half of patients with AIS, who were selected
for endovascular treatment, achieved GCO following successful
revascularization (42, 49). We believe that the low positive predic-
tive value (50%) of these tests is due to the inability of different
non-invasive tests to distinguish between normal and ischemic
(but viable) cerebral tissue on one hand, and its inability to distin-
guish between ischemic tissue and irreversible ischemia early on,
on the other hand, due to the time delay needed for the structural
changes of cerebral infarction to become readily apparent (42, 49,
56, 57).
For a screening test to be a useful patient selection tool, it must
be highly correlated to the functional clinical outcome. In our
opinion, existing non-invasive tests do not meet this requirement.
This relatively low positive predictive value of the different imag-
ing techniques used hasmultiple implications. First, it hinders our
ability to develop an accurate prognosis for the patient and his
or her family. Second, we may proceed with a costly treatment
without benefit (futile recanalization). In some cases, the patient
may experience worsening clinical symptoms due to increasing
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FIGURE 6 | CIS=2. (A) Occlusion of the left ICA. (B) Injection of the
right ICA demonstrates filling of the left ACA territory through the
Acom with partial opacification of the fronto–parietal lobes via pial
collaterals. (C) Injection of the left vertebral artery demonstrates partial
opacification of the left temporal lobes via pial collaterals. (D) Delayed
venous phase of the right ICA and left vertebral showing approximately
two-third of the ischemic territory (left middle MCA) to demonstrate capillary
blush.
the cerebral injury by reperfusion-mediated vasogenic edema, or
perhaps even hemorrhagic transformation by forcing blood into
the infarcted area (harmful revascularization). Finally, and more
importantly, we may deny the treatment to patients based on
an artificial time window, for whom IAT may still be beneficial.
Increasing the accuracy of patient selection is clearly needed.
The Capillary Index Score
The role of collaterals in improving clinical outcome in patients
with AIS is now widely accepted (58–60). Recently, using the
American Society of Interventional and Therapeutic Neuroradi-
ology/Society of Interventional Radiology (ASITN/SIR) collateral
score (58), the Interventional Management of Stroke (IMS) III
investigators were able to confirm the previous reports on the
positive effect of better collaterals on revascularization and clinical
outcome (59).
The Capillary Index Score (CIS) was first introduced from the
Borgess Medical Center-Acute Ischemic Stroke Registry (BMC-
AIS Registry) data (61) with the aim to improve the criteria
for patient selection in AIS. The presence of capillary blush was
proposed to be a marker of residual viable tissue, with its absence
implying irreversible ischemia. The CIS is a simple 4-point scale
ranging from 0 to 3. The ischemic territory on the frontal view of
a diagnostic cerebral angiogram (DCA) is divided in three equal
segments (Figure 3). If a segment does not demonstrate a capillary
blush it is assigned 0 points, whereas it is assigned 1 point if it
exhibits capillary blush. The final CIS is the sum of these three
segmental scores (Figures 4–7). Therefore, CIS of 0 means no
angiographic capillary blush was found in the whole ischemic
territory, whereas a CIS of 3 signifies that the whole ischemic area
exhibits capillary blush. CIS 2 or 3 (1/3 of the ischemic area has
no capillary blush) is considered favorable CIS (fCIS) and it was
found to be a prerequisite for a GCO in BMC-AIS registry (61).
A CIS of 0 or 1 was considered a poor score CIS (pCIS), and
no patients with pCIS had a GCO despite good revascularization
(61). The merit of the CIS as a method for patient selection was
further validated in a recent IMS I and II subgroup analysis (20).
Of patients with fCIS and good revascularization (mTICI, score
2b or 3), 100% achieved GCO, while patients with pCIS invariably
did worse than the natural history of the disease estimated at
25% GCO, as shown by the PROACT II study, independent of
revascularization status (Table 2) (3). Recently, we applied the
CIS to a subgroup of IMS III cohort and found almost identical
findings (Al-Ali, Firas et al. Relative Influence of Capillary Index
Score, Revascularization and Time on Stroke: Outcomes from the
IMS III trial. Submitted to Stroke February 2015).
The percentage of fCIS, which was a prerequisite for GCO, was
found to be 42% in the BMC-AIS registry and 46% in the IMS
I, II subgroup analysis (20, 57), all hovering around 50%, which
strengthens our belief in “the 50% barrier” hypothesis.
Ischemic Territory vs. the Site of Vascular
Occlusion
Central to the concept of CIS is the concept of ischemic territory.
We define ischemic stroke by the ischemic territory instead of
the site of vascular occlusion since we believe that it gives a more
accurate estimation of stroke extension. The ischemic territory
is defined as the area of the brain that lacks antegrade flow. All
or a portion may receive its blood supply in retrograde fashion
through pial collaterals. For example, in a patient with internal
carotid artery (ICA) occlusion, a few radically different scenarios
are possible. In one scenario, the patient has congenital absence
of the Acom and the Pcom arteries (Figure 8). This patient’s
ischemic territory will include the entire ipsilateral middle and
anterior cerebral artery territories. In a different scenario with
the exact same ICA occlusion, but with Acom artery present and
well-developed, the anterior cerebral artery territory ipsilateral
to the vascular occlusion will receive an antegrade blood supply
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FIGURE 7 | CIS= 3.
FIGURE 7 | Continued
(A) Injection of the left ICA demonstrates occlusion of proximal left MCA
(ischemic territory= left MCA) with partial opacification of the left
fronto-parietal lobes via pial collaterals of the left ACA. (B) Injection of the left
vertebral artery demonstrates partial opacification of the left temporal lobes
via pial collaterals. (C) Delayed venous phase of the left ICA and the left
vertebral artery. All the ischemic territory (left MCA) demonstrates capillary
blush. CIS=3.
TABLE 2 | CIS vs. Outcome.
fCIS:% of mRS, 0–2 pCIS:% of mRS, 0–2
BMC-AIS (TIMI 0,1) 0 0
BMC-AIS (TIMI 2,3) 60 0
BMC-AIS (TIMI 3) 83 0
IMS I, II (TIMI 0,1) 33 0
IMS I, II (mTICI 2,3) 86 13
IMS I, II (mTICI 2b,3) 100 20
from the counter lateral ICA, through the patent Acom artery
so the ischemic territory will encompass only the MCA territory
(Figure 9). Hence, due to multiple possible scenarios when using
the site of vascular occlusion to describe the ischemic stroke, we
believe that defining the stroke by its territory is a more accurate
approach.
The CIS Limitation
The main limitation of the CIS is the need to perform a full DCA
during intervention. However, we believe the significant informa-
tion obtained through the CIS by examining the DCA, mainly
how to guide patient selection combined with the elimination
of an arbitrary time window greatly outweighs the minimal risk
associated with adding a few injections for a requiredDCA during
intervention.
CIS vs. Non-Invasive Testing
Interestingly, the fCIS and pCIS groups had almost identical
values concerning time from stroke onset, the ASPECT score, and
the National Institutes of Health Stroke Scale (NIHSS) scores in
the BMC-AIS registry and the IMS I, II subgroup analysis (20,
61). The relationship betweenCIS and different perfusion imaging
parameters was evaluated in the DEFUSE II trial. Although there
was a good general agreement between the CIS score and the time
to maximum values >6 and >10 (Tmax> 6 and Tmax> 10), low
CIS correlatedwith highTmax> 6. Therewas a significant overlap
between the different CIS and the Tmax values, which makes it
impossible to differentiate between the fCIS and pCIS based solely
on the MRI perfusion parameter. (Oral presentation at the Inter-
national Stroke Conference, SanDiego, CA, USA, February 2014).
These findings imply that the CIS provides different information
than currently available from non-invasive tests, which cannot be
extrapolated with confidence. Furthermore, none of these non-
invasive tests has a similar threshold to the CIS (f vs. pCIS) that
can be used confidently in patient selection. As shown, even with
the most useful non-invasive test today, MRI diffusion/perfusion
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FIGURE 8 | Vascular occlusion and ischemic territory. This patient
has occlusion of the right ICA and a congenital absence of the anterior
and posterior communicating arteries (Acom, Pcom). The resulting
ischemic territory is the right MCA and ICA. (A) Frontal view of the
injection of the right common carotid artery demonstrating no intracranial
capillary blush. (B) Frontal view of the injection of the left common carotid
artery demonstrating no collateral flow to the right hemisphere through the
interior cerebral artery. (C) Frontal view of the injection of the right
vertebral artery demonstrating no collateral flow to the right interior carotid
artery territory.
FIGURE 9 | Vascular occlusion and ischemic territory. This patient has occlusion of the left internal carotid artery (ICA), but has a well-developed anterior
communicating artery (Acom). The resulting ischemic territory is only the left MCA territory.
imaging, only 50% of patients who achieve good revascularization
have a GCO (49).
The Relative Importance of CIS,
Revascularization, and Time
Several important observations were made after applying the CIS
retrospectively on different registries and trials [(20, 61), Al-Ali,
Firas et al. Relative Influence of Capillary Index Score, Revascu-
larization and Time on Stroke: Outcomes from the IMS III trial.
Submitted to Stroke February 2015]. First, fCIS was almost a pre-
requisite for GCO following revascularization. In other words,
when good revascularization (TIMI 2, 3) was achieved on patients
with pCIS, it was futile (no clinical improvement). Revascular-
ization mattered only when patients had excellent collaterals, as
indicated by fCIS. Next, and despite the fact that fCIS was almost
a prerequisite for GCO, its presence alone was not sufficient to
guarantee GCO. In the IMS I and II, patients with fCIS had 100
vs. 38% GCO with or without good recanalization, respectively
(20). These observations demonstrate the concomitant impor-
tance of recanalization and the fact that fCIS is an indicator of
ischemic but contemporaneously viable tissue, but not an indi-
cator of perpetually viable tissue. Recanalization is still required.
If these observations are supported in a prospective trial, it may
significantly change the AIS treatment algorithm, where IAT
could be offered to all patients with fCIS but not patients with
pCIS, regardless of time of ictus. This will constitute a radical
shift of the present approach and liberate the decision making
from an arbitrary time window, in favor of a more physiological
basis.
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FIGURE 10 | Proposed patient selection algorithm for AIS.
Proposed Patient Selection Algorithm
We recognize that the merit of the CIS still needs to be proven
in a multicenter prospective study; however, we believe the CIS
hypothesis will be proven true due to its ability to explain the
results of ischemic stroke trials.
Since most patients will improve to a variable degree with
time and physical therapy, we believe that IAT should be offered
to patients suffering from a large stroke (NIHSS< 8), with the
only exception being aphasia (Figure 10). Of those patients
who are Clinically Eligible, a non-enhanced head CT is obtained
followed by CTA. These non-invasive tests can first rule out
stroke mimics and identify patients with already visible signs of
structural changes due to large irreversible ischemia (i.e., hypo-
density in >1/3 MCA territory on head CT). If no such find-
ings are identified, CTA will help confirm the vascular occlu-
sion and its location. Patients with no counter-indication to
treatment and proven large vessel occlusion (CT Eligible) are
offered IAT. A full DCA is performed on these patients to
obtain the CIS. Only patients who demonstrate fCIS (CIS Eli-
gible) should be offered IAT since revascularization on patients
with pCIS will be futile and possibly harmful (Figure 10).
If these steps are taken,we predict a significant increase in the ratio
of GCOs between treated and untreated patients on the order of
5–6, instead of the current 1.6–1.7 ratio that exists currently (3,
10–13), by the virtue of significantly decreasing the percentage of
futile and harmful revascularization.
Conclusion
The current approach for treating AIS is based on arbitrary time
windows and revascularization, but we believe collaterals also
need to be taken into account. We argue that only approximately
50% of all patients with AIS have robust enough collaterals to
permit GCOs following treatment, a concept we call the 50%
barrier. Previous and ongoing genetic work should shed light
on this interesting possibility in the near future. The CIS can
identify patients with viable tissue, who are therefore candidates
for treatment, and dispose of the arbitrary time window.
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